Society Logo
ME/CFS Australia Ltd
Please Click Here To Donate ME/CFS Australia (SA) Inc
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
266 Port Road,
Hindmarsh,
South Australia 5007
Ph: 1300 128 339

Office Hours:
Wednesdays, 10am-3pm


FIBROMYALGIA HELP:
Contact
Fibromyalgia SA
at the
Arthritis Foundation of SA
118 Richmond Road,
Marleston 5033
Ph: (08) 8379 5711

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form 2014 (PDF, 243KB)
Why become a member?

Belgian trial of sodium oxybate for Chronic Fatigue Syndrome announced

Tuesday 22 May 2012

 

From ProHealth:

 

ProHealthBelgian Trial of Sodium Oxybate for Chronic Fatigue Syndrome Announced

ProHealth.com
May 3, 2012

May 2: Belgian investigators at University Hospital, Ghent, have announced they’re preparing to enroll about 65 patients with chronic fatigue syndrome (ME/CFS) but without fibromyalgia in a placebo controlled, randomized, double blind, cross-over efficacy trial of the experimental drug sodium oxybate (Xyrem). They apparently expect to launch in June.

Sodium oxybate is a short-acting central nervous system depressant that has gained publicity for its abuse as “the date-rape drug.” It is FDA approved to prevent episodes of cataplexy (sudden episodes of muscle weakness) or narcolepsy (sudden uncontrollable episodes of sleep during day). Currently a costly drug, physicians have tried it off-label for treatment of ME/CFS sleep & fatigue, and it has shown some promise in trials for treatment of fibromyalgia insomnia, fatigue and pain; but so far with questionable promise of FDA approval for the fibromyalgia diagnosis.

The primary outcome measure in the Belgian trial will be effect on fatigue in ME/CFS. Secondary measures, sleepiness, sleep quality, general health, and pain. The researchers suggest the findings may support a better understanding of “the enigmatic relationship between sleep and fatigue.”

According to principal investigator An Mariman, MD, both the subjects receiving sodium oxybate and the group receiving placebo (fake medication) will be treated in their home with varying amounts of medication each night over a period of weeks.

For details and inclusion/exclusion criteria, see the study’s ClinicalTrials.gov description - http://clinicaltrials.gov/ct2/show/NCT01584934.

For questions, e-mail principal investigator An Mariman, MD: An.Mariman@ugent.be

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus

Previous Previous Page